Danaher

DHR

Börsenwert 161 Mrd. $

DHR's Q3 results are due Oct. 21, with growth in Biotechnology, Diagnostics and Life Sciences expected to boost revenues, while rising costs and currency headwinds weigh on earnings.

Evaluate the expected performance of Danaher (DHR) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Danaher (DHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Danaher (DHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Both Danaher and GE Healthcare are trading at attractive valuations after recent declines. Upcoming earnings reports are key catalysts for potential stock rebounds.

.Danaher (DHR), one of the world's largest providers of medical diagnostics and laboratory equipment, recently announced plans to launch its first AI-powered autonomous laboratory, scheduled to operate at commercial scale in early 2027. While market trading barely moved the stock on the announcement date, the news marks a quiet turning point for life science automation.

Collaboration will bring together NVIDIA AI technologies and Danaher's scientific instruments, laboratory workflows and data WASHINGTON, Oct. 14, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced a collaboration with NVIDIA to advance autonomous science and help accelerate the pace of scientific discovery. As part of Danaher's broader effort to shape the future of AI-enabled science, the companies are working to combine Danaher's scientific instrumentation, automation technologies, laboratory workflow software and domain expertise with NVIDIA accelerated computing and AI technologies.

WASHINGTON, Oct. 12, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or "the Company") today announced the appointment of Daniel L. Comas and Robert Hershberg, M.D.